doi: 10.1034/j.1399-3003.2000.016003534.x 229 RingelJ.RamlowA.BockC.SheriffA
Study Design : All participants received semaglutide 2.4 mg for 20-week run-in period Participants who lost 5% body weight were then randomized to: Continue semaglutide (n=535) Switch to placebo (n=268) Follow-up: Additional 48 weeks (68 weeks total) Results : Continued semaglutide group : Lost additional 7.9% body weight (total 17.4% from baseline) Switched to placebo group : Regained 6.9% body weight (net 9.8% loss from baseline) Interpretation : This trial demonstrates that: Most participants regain significant weight when semaglutide is discontinued Continuing medication supports ongoing weight loss beyond initial reduction Long-term medication use is typically necessary for sustained results Understand the Differences Between FDA-Approved and Compounded Medications Tirzepatide Clinical Evidence: SURMOUNT Trial Program SURMOUNT-1: Primary Efficacy Trial Citation : Jastreboff AM, et al
Its linked to higher homocysteine levels , a risk factor for heart disease, neural tube defects, and pregnancy complications [4]
Compounded versions are not FDA-approved and have not undergone the same rigorous testing for efficacy, safety, and quality
BPC-157 is a synthetic pentadecapeptide (a peptide made up of 15 amino acids) based on a segment from a natural peptide (BPC) derived from human gastric juice.3 4 Insider Tip: Other names for BPC-157 are body protection compound 157, BPC-15, bepecin, PLD-116, PL-10, and PL-14736. Some also refer to BPC-157 as the Wolverine peptide due to its potential to support healing
Additionally, the weight-loss effects of early GLP-1s were modest compared to newer formulations, limiting their appeal for obesity treatment
.webp)
